

















Journal of the American College of Cardiology Vol. 61, No. 6, 2013
© 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.056EDITORIAL COMMENT
Discontinuation
of Rivaroxaban
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Late in 2011, rivaroxaban became the first factor Xa
inhibitor to receive regulatory approval for the prevention of
stroke in patients with atrial fibrillation (AF), based largely
on the results of the phase III ROCKET AF (Rivaroxaban
Once-Daily, Oral, Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation) trial (1), which
enrolled 14,264 patients in a double-blind, double-dummy
design. The ROCKET AF trial clearly established the
noninferiority of rivaroxaban compared with warfarin for
the primary endpoint of stroke or systemic embolism. The
superiority of rivaroxaban was less clear: statistical superior-
ity was shown (hazard ratio: 0.79, p  0.02) in the
s-treated safety population, which counted only on-
reatment events (during treatment or 2 days or fewer after
tudy drug discontinuation), but not in a full intention-to-
reat analysis, which also considered events occurring out-
ide the on-treatment window (hazard ratio: 0.88, p 
.12).
See page 651
In their initial trial publication (1), the ROCKET AF
investigators reported that stroke or systemic embolism
event rates were numerically higher, but not statistically
different, between rivaroxaban and warfarin after early,
permanent drug discontinuation, which occurred in nearly
one third of the patients during the trial. In contrast, a
significantly higher event rate was seen with rivaroxaban as
compared with warfarin patients from 3 to 30 days after
study drug discontinuation at the end of the trial, when
most patients were transitioned to open-label vitamin K
antagonist (VKA) therapy.
This latter finding raised particular concern during the
Food and Drug Administration (FDA) review process and
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may be associated with a prothrombotic rebound effect (2).
The notion of a rebound effect has been hypothesized for
warfarin, but is of questionable clinical relevance (3). In the
case of rivaroxaban, there is not a clear mechanistic hypoth-
esis for a rebound effect. Nonetheless, the clinical events at
the end of the ROCKET AF trial have raised questions
about this, as well as about the appropriateness of once-daily
dosing of this drug, which has a half-life of 5 to 9 h, in AF
patients. The FDA’s concern about these end-of-study
events culminated in a black box warning of “an increased
risk of thrombotic events” with rivaroxaban discontinuation.
In this issue of the Journal, Patel et al. (4) begin to bring
more perspective and clarity to the previous observations by
presenting more comprehensive and detailed data surround-
ing clinical events that occurred during all interruptions or
discontinuations of study medication during the ROCKET
AF trial. The authors report on the rates of stroke and
systemic embolism as well as other secondary outcome
measures under 3 sets of circumstances: 1) temporary
interruptions of the blinded study drug, which were com-
mon ( 8,000 occurrences) and had a median duration of 6
days; 2) 3 to 30 days after early permanent discontinuation
of the study drugs (n  4,895); because of adverse events,
withdrawals, and suspected or confirmed primary endpoint
events; and 3) 3 to 30 days after permanent study drug
discontinuations at the end of the study in surviving patients
without suspected primary end point events or early perma-
nent discontinuation (n  9,239).
Temporary interruptions of the study drug were associ-
ated with event rates of roughly 5 to 6 per 100 patient-years
and did not differ between rivaroxaban and warfarin pa-
tients. Early permanent discontinuations were associated
with much higher event rates (23 to 25 per 100 patient-
years), but again did not differ based on assigned therapy. It
should be noted that event rates in this group were exaggerated
by the inclusion of patients whose study drug discontinuation
was prompted by a suspected primary endpoint event: approx-
mately 8% of these patients went on to have a first or new
rimary endpoint event between 3 to 30 days after stopping
heir blinded therapy. After excluding this group, event rates
ere 8.1 and 9.4 per 100 patient-years in the rivaroxaban
nd warfarin arms, respectively.
As previously reported (1), and in contrast to the results
uring temporary or early permanent discontinuations of
tudy drug described above, a relatively large difference in
troke or systemic embolism rates for rivaroxaban versus
arfarin patients was seen 3 to 30 days after the end of the
tudy (22 vs. 6 events and 6.4 vs. 1.7 per 100 patient-years,
azard ratio: 3.72, p  0.01). Somewhat surprisingly, the
new analysis also reveals an increased risk of major bleeding
in rivaroxaban patients (7.3 vs. 2.0 events per 100 patient-
years, hazard ratio: 3.62, p  0.003) during this same
timeframe.
660 Reynolds JACC Vol. 61, No. 6, 2013
Discontinuation of Rivaroxaban February 12, 2013:659–60What explains this observation of increased risk for
rivaroxaban patients only at the end of the study? Although
approximately 92% of patients in both study arms began
open-label VKA therapy after the trial ended, as the authors
show, there seems to have been an almost immediate
imbalance in anticoagulation coverage between the groups
during this transition. Roughly 60% of patients who had
received warfarin during the trial had an international
normalized ratio (INR) of 2.0 or more when next measured
3 days after trial end, and 81% had an INR 2.0 at least
once in the 30-day post-trial period. In contrast, only
approximately 25% of rivaroxaban patients had an INR
2.0 in the first 7 to 10 days after study end, and only 49%
ever became therapeutic within 30 days. Independent anal-
ysis of this data by the FDA corroborates that the quality of
VKA anticoagulation in the rivaroxaban patients was poorer
during this timeframe than in the warfarin patients—and
also shows that the last recorded INR preceding end-of-
study stroke events was subtherapeutic roughly two thirds of
the time (5).
The authors’ implication from these data is that the most
likely explanation for the observed risk in the post-study
transition period is not that rivaroxaban has some property
resulting in a rebound effect, but rather that the high-risk
patients enrolled in the ROCKET AF trial (mean age: 73
years, mean CHADS2 score: 3.5) had a substantial differ-
ence in anticoagulation coverage during this period, and the
event rates merely reflect the unmasking of their underlying
risk. Indeed, the event rates reported in the current report
seem to be consistent with this notion: during temporary
interruptions of either study drug and during the post-study
transition period for rivaroxaban patients, the event rates
were approximately 5 to 6 per 100 patient-years, a rate quite
close to what would be predicted based on their baseline
CHADS2 scores (6). During the post-study transition
period for warfarin patients, the event rate of 1.7 per 100
patient-years was close to that observed in the on-treatment
analysis during the trial (1).
Although this explanation is fairly persuasive, the evi-
dence that the post-study excess stroke risk in rivaroxaban
patients was the result of inadequate VKA therapy remains
somewhat circumstantial. The INRs were not collected as
carefully during the post-trial period as during the in-trial
period (5); thus, a statistical analysis adjusting for INR
values or time in therapeutic range may not be possible.
More importantly, the authors do not provide any informa-
tion on the use of bridging therapies. Bridging with unfrac-
tionated or low–molecular-weight heparin was raised as a
consideration, but was not mandated by the study protocol
during either temporary interruptions or at the end of the
study. The bleeding rates reported in the current study also
are counterintuitive: if the excess strokes in rivaroxaban
patients were the result of underanticoagulation in the
post-trial period, then why did these patients also have a
higher bleeding risk? The investigators will need to scruti-nize this large trial database further to understand these
issues more fully.
What is clearest from this important subanalysis of the
ROCKET AF trial is that bad things will happen to
high-risk AF patients if they are left untreated with effective
anticoagulant therapy for sustained periods—and that in a
population as large as this one, it does not take much time
for those events to begin to accumulate. Although the black
box warning may seem to single out rivaroxaban unfairly in
delivering this message, it at least serves as a reminder that
interruptions and transitions with short-acting anticoagu-
lant drugs must be planned and managed carefully. Of
course, defining what carefully means requires much more
evidence than is available currently. In invasive electrophys-
iology, we have learned only recently that bridging strategies
generally do more harm than good compared with doing
procedures such as cardiac rhythm device implantation or
AF ablation under uninterrupted warfarin therapy (7,8).
The current study also highlights the particularly high
short-term risks present under the circumstances that re-
sulted in early permanent discontinuation of the study
drugs, particularly those associated with adverse events or
suspected strokes or transient ischemic attacks. These chal-
lenging scenarios point to continued unmet needs in the
area of stroke prevention in AF.
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